Top > Search of International Patents > MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE

MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE

Foreign code F200010070
File No. 5992
Posted date May 15, 2020
Country WIPO
International application number 2019JP003802
International publication number WO 2019151514
Date of international filing Feb 4, 2019
Date of international publication Aug 8, 2019
Priority data
  • P2018-018622 (Feb 5, 2018) JP
Title MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE
Abstract Provided is a monocyte differentiation inducer which contains albendazole as an active ingredient.
Outline of related art and contending technology BACKGROUND ART
In blood disease, hematopoietic stem cells is inhibited due to the branching processes in the absence of a disease, such as leukemia, aplastic anemia, cost engineer and syndrome.
Leukemia, hematopoietic stem cells (or slightly differentiated cell) to the tumor is considered to be caused by a disease. The chemotherapy treatment is basically in the cure, chemical therapy complications organ toxicity to withstand the general health and organ function needs to be sufficiently maintained because, in older patients often chemotherapy cannot be applied, if there are temporarily no no healing in a patient older not present. For such patients with fewer side effects to the new therapeutic agent is required.
Differentiation as methods of treatment for leukemia with fewer side effects known induction therapy. Differentiation induction therapy, progenitor cells remain at the state of the continued proliferation differentiation leukemia cells, a normal maturation for kill the lifetime of the white original, many anti-cancer chemotherapeutic agent or treatment of leukemia cells such as direct disruption as compared to less side effects. However, an acute promyelocytic leukemia (ATRA) all-trans retinoic acid and/or arsenic is used as a differentiation of neutrophils to the effectiveness of the therapy differentiation induction is established, other leukemia is currently effective differentiation induction therapy is not established. Further, an acute promyelocytic leukemia ATRA of the resistance is present. Leukemia in a wide variety of medical therapies to induce the differentiation of the new effective in strongly demanded.
Aplastic anemia due to some abnormality in the hematopoietic stem cell differentiation and inhibit the disease course, cost man syndrome (alias: severe congenital neutropenia) bone marrow granulocyte-cell maturation and a poor, neutrophils decrease in the group. Leukemia, aplastic anemia, hematopoietic stem cell such as the cost of man syndrome is inhibited due to the branching processes in the disease, decrease in the hematopoietic function, neutrophils and monocytes cell infection is reduced and becomes a problem. As a countermeasure of the bacterial infection in these diseases are, at present, granulocyte-colony stimulating factor (G-CSF) to induce the differentiation of neutrophils such as the agents are administered, G-CSF administration does not increase even after the neutrophils also exist. In order to improve symptoms in these diseases, to promote differentiation of hematopoietic stem cells from the blood to induce the differentiation of valid during the desired agent.
Scope of claims (In Japanese)[請求項1]
 アルベンダゾールを有効成分として含む、単球分化誘導剤。

[請求項2]
 造血幹細胞の分化過程の阻害を伴う疾患を治療するための、請求項1に記載の単球分化誘導剤。

[請求項3]
 該造血幹細胞の分化過程の阻害を伴う疾患が、再生不良性貧血、コストマン症候群、または白血病もしくはその類縁疾患から選択される、請求項2に記載の単球分化誘導剤。

[請求項4]
 該造血幹細胞の分化過程の阻害を伴う疾患が、白血病またはその類縁疾患である、請求項2または3に記載の単球分化誘導剤。

[請求項5]
 該白血病またはその類縁疾患が、慢性骨髄性白血病、急性骨髄性白血病または骨髄異形成症候群である、請求項2~4のいずれか1項に記載の単球分化誘導剤。

[請求項6]
 分化誘導療法として使用される、請求項4または5に記載の単球分化誘導剤。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • Inventor
  • MORITA, Ken
  • ADACHI, Souichi
  • HAGIWARA Masatoshi
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close